Coherus Biosciences | CHRS - Current Liabilities

Stock Price
1.61
Daily Change
-0.40 -19.90%
Monthly
0.63%
Yearly
36.44%
Q1 Forecast
2.39

Coherus Biosciences reported $372.3M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Akebia Therapeutics USD 133.38M 14.66M Sep/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 182.23M 3.71M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
Baxter International USD 2.97B 805M Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Coherus Biosciences USD 372.3M 108.67M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Fujifilm JPY 1.2T 44.21B Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Myriad Genetics USD 148M 51.9M Sep/2025
Pacira USD 107.08M 206.09M Sep/2025
Perrigo USD 1.15B 19.2M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Teva Pharmaceutical Industries USD 13.46B 1.96B Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xencor USD 86.48M 9.6M Sep/2025
Zoetis USD 2.24B 428M Dec/2025